- Home
- ENOV
ENOV
Enovis Corporation
as 09-18-2025 4:00pm EST
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 1.6B | IPO Year: | 2008 |
| Target Price: | $51.00 | AVG Volume (30 days): | 970.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.46 - $49.83 | Next Earning Date: | 11-05-2025 |
| Revenue: | $2,189,576,000 | Revenue Growth: | 14.40% |
| Revenue Growth (this year): | 9.13% | Revenue Growth (next year): | 6.39% |
Stock Insider Trading Activity of Enovis Corporation (ENOV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McDonald Damien | ENOV | Chief Executive Officer | Sep 11 '25 | Buy | $30.97 | 6,457 | $199,973.29 | 102,753 | |
| Tandy Bradley J | ENOV | SVP and Chief Legal Officer | Aug 22 '25 | Buy | $31.41 | 3,200 | $100,512.00 | 43,515 | |
| BERRY PHILLIP BENJAMIN (BEN) | ENOV | SVP, Chief Financial Officer | Aug 20 '25 | Buy | $29.71 | 2,500 | $74,275.00 | 116,729 | |
| PRYOR DANIEL A | ENOV | EVP, Strategy & Business Dev. | Aug 13 '25 | Buy | $28.90 | 10,000 | $289,000.00 | 161,115 |
Latest Enovis Corporation News
ENOV Breaking Stock News: Dive into ENOV Ticker-Specific Updates for Smart Investing
StockStory
3 months ago
5 Insightful Analyst Questions From Enovis’s Q1 Earnings Call
Insider Monkey
3 months ago
Jefferies Maintains a Buy on Enovis (ENOV), Sets a $60 PT
StockStory
3 months ago
Entegris, Herc, Enovis, Commercial Vehicle Group, and DexCom Shares Skyrocket, What You Need To Know
StockStory
3 months ago
3 Stocks Under $50 in Hot Water
StockStory
3 months ago
1 Growth Stock to Target This Week and 2 to Be Wary Of
Argus Research
3 months ago
ENOV: Raising target price to $35.00
GlobeNewswire
3 months ago
Enovis to Participate in Upcoming Investor Conferences
StockStory
4 months ago
3 Out-of-Favor Stocks in the Doghouse
Compare ENOV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENOV Enovis Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.